A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Nintedanib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 07 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Nov 2018.
- 16 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.